文献速递青光眼小儿眼科与斜弱视

接受不同屈光矫正的原发性先天性青光眼患儿的视觉结局:CLEVR-PCG随机临床试验

Visual Outcomes of Children With Primary Congenital Glaucoma Receiving Different Refractive Corrections: The CLEVR-PCG Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项在中国广州中山眼科中心开展的随机临床试验纳入56例(4-15岁)手术后的原发性先天性青光眼且眼镜矫正反应不佳的患儿,比较硬性透气性角膜接触镜(RGPCL)与继续佩戴眼镜12个月的视觉结局。1年时RGPCL组最差眼最佳矫正视力改善优于眼镜组(调整后治疗差异-0.19 logMAR,95%CI -0.36至-0.02,P=0.03),对比敏感度改善也更明显,且未发生严重不良事件。

要点

  • RGPCL组1年时最差眼BCVA改善0.31 logMAR,眼镜组改善0.12 logMAR,调整后差异-0.19 logMAR(P=0.03)。
  • RGPCL组62.5%患儿BCVA提高2行及以上,眼镜组37.5%(OR 6.83,95%CI 1.81-25.73,P=0.01)。
  • RGPCL组50.0%达到近立体视≤60弧秒,眼镜组25.0%(OR 6.96,95%CI 2.41-6.51,P=0.001)。

核心结论

  • 研究结果提示,对于原发性先天性青光眼术后患儿,RGPCL在改善视力和对比敏感度方面优于继续佩戴眼镜。
  • 研究结果支持对原发性先天性青光眼术后患儿使用RGPCL,包括基线视力较差或眼镜矫正反应不佳者。

研究设计与样本

  • 随机临床试验,于2022年4月21日至2023年8月21日在中国广州三级转诊中心中山眼科中心开展。
  • 纳入56例(4-15岁)经手术治疗的PCG且眼镜矫正反应不佳的患儿,随机分为RGPCL组29例与眼镜组27例,干预12个月并联合标准化弱视遮盖。
  • 主要结局为12个月时最差眼BCVA变化,采用ETDRS图表翻转E视标测量,患儿佩戴当前最佳屈光矫正。

主要发现

  • 56例随机化参与者中48例(85.7%)完成至少1次随访并纳入主要分析;12个月时RGPCL组29例中22例(76.0%)、眼镜组27例中19例(70.4%)完成最终访视。
  • 基线最差眼球镜等效值RGPCL组-6.55(6.43)D vs 眼镜组-5.17(5.27)D,基线BCVA 0.99(0.71) vs 1.02(0.74) logMAR,基线眼压14.98(3.14) vs 13.36(3.92) mm Hg。
  • 1年时RGPCL组BCVA改善0.31(0.28) logMAR vs 眼镜组0.12(0.33) logMAR,调整后治疗差异-0.19 logMAR(95%CI -0.36至-0.02,约10个字母,P=0.03)。
  • BCVA提高2行及以上者RGPCL组24例中15例(62.5%) vs 眼镜组24例中9例(37.5%),OR 6.83(95%CI 1.81-25.73,P=0.01)。
  • 对比敏感度函数改善RGPCL组0.40(0.27) vs 眼镜组0.13(0.32),调整后治疗差异0.24 log单位(95%CI -0.01至0.49,P=0.04);近立体视≤60弧秒者RGPCL组12例(50.0%) vs 眼镜组24例中6例(25.0%),OR 6.96(95%CI 2.41-6.51,P=0.001);无严重不良事件发生。

关键数值与推荐

  • 主要结局为12个月时最差眼BCVA变化,采用ETDRS图表翻转E视标测量。
  • BCVA提高2行及以上:RGPCL组62.5% vs 眼镜组37.5%(OR 6.83,95%CI 1.81-25.73,P=0.01)。
  • 近立体视≤60弧秒:RGPCL组50.0% vs 眼镜组25.0%(OR 6.96,95%CI 2.41-6.51,P=0.001)。

临床怎么用

  • 研究结果支持对原发性先天性青光眼术后患儿使用RGPCL,包括基线视力较差或眼镜矫正反应不佳者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Primary congenital glaucoma (PCG) surgery often leaves residual visual impairment in children. Evidence comparing rigid gas-permeable contact lenses (RGPCLs) vs spectacles for rehabilitation is needed. OBJECTIVE: To compare the use of RGPCLs vs continued spectacle wear for improving visual outcomes for children after PCG surgery. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at Zhongshan Ophthalmic Center, a tertiary referral center in Guangzhou, China, from April 21, 2022, to August 21, 2023. Participants comprised 56 children (aged 4-15 years) with surgically managed PCG and poor spectacle response. Data were analyzed from October 11, 2023, to March 21, 2024. INTERVENTIONS: RGPCLs (n = 29) vs spectacles (n = 27) for 12 months, plus standardized amblyopia patching. MAIN OUTCOMES AND MEASURES: The primary outcome was change in worse-eye best-corrected visual acuity (BCVA) at 12 months measured by the Early Treatment Diabetic Retinopathy Study chart with tumbling-E optotypes with children wearing their current best refractive correction. Secondary outcomes included contrast sensitivity function and near stereoacuity. RESULTS: Among 56 (of a total of 83 screened participants) randomized participants, 48 (85.7%) completed at least 1 follow-up visit and were included in the primary analysis. Baseline demographic and ocular characteristics for the RGPCL group vs the spectacles group included a mean (SD) age of 7.7 (2.7) vs 7.2 (3.2) years, 13 (54.2%) vs 14 (58.3%) male, and 11 (45.8%) vs 10 (41.7%) female. At 12 months, 22 of 29 participants (76.0%) in the RGPCL group and 19 of 27 participants (70.4%) in the spectacles group completed the final visit. The mean (SD) baseline worse-eye spherical equivalent was -6.55 (6.43) vs -5.17 (5.27) diopters, the mean (SD) BCVA was 0.99 (0.71) vs 1.02 (0.74) logMAR (approximate Snellen equivalent 20/200), and the mean (SD) intraocular pressure was 14.98 (3.14) vs 13.36 (3.92) mm Hg in the RGPCL vs the spectacles group, respectively. At 1 year, the RGPCL group had greater BCVA improvement (mean [SD], 0.31 [0.28] vs 0.12 [0.33] logMAR; adjusted treatment difference, -0.19 logMAR; 95% CI, -0.36 to -0.02 logMAR [approximately 10 letters]; P = .03). Achievement of 2 or more lines of BCVA improvement occurred in 15 of 24 participants (62.5%) in the RGPCL group vs 9 of 24 participants (37.5%) in the spectacles group (odds ratio, 6.83; 95% CI, 1.81-25.73; P = .01). The RGPCL group had greater contrast sensitivity function improvement (0.40 [0.27] vs 0.13 [0.32]; adjusted treatment difference, 0.24 log units; 95% CI, -0.01 to 0.49; P = .04). Near stereoacuity of 60 arcseconds or less was achieved by 12 participants (50.0%) vs 6 of 24 participants (25.0%) (odds ratio, 6.96; 95% CI, 2.41-6.51; P = .001). No serious adverse events occurred. CONCLUSIONS AND RELEVANCE: These findings suggest that RGPCLs provided superior visual acuity and contrast sensitivity improvement vs continued spectacle wear for children after PCG surgery. These findings support using RGPCLs for children undergoing PCG surgery, including those with worse baseline visual acuity or poor spectacle response. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2100043776.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Jiang J, Hu Y, Zhu Y, et al. Visual Outcomes of Children With Primary Congenital Glaucoma Receiving Different Refractive Corrections: The CLEVR-PCG Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 41196588. doi:10.1001/jamaophthalmol.2025.3976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。